Home >> Tag Archives: Astute Medical—

Tag Archives: Astute Medical—

Test predicts AKI risk in sepsis patients, 9/16

September 2016—Astute Medical said in a statement that a new ancillary analysis of two multicenter studies using the company’s NephroCheck Test demonstrates that urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases 2 (TIMP-2), the biomarkers detected and measured by the test, accurately predict acute kidney injury in septic patients with or without other organ failures.

Read More »

FDA OKs marketing of AKI risk-assessment test, 11/14

November 2014—The Food and Drug Administration is allowing the marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury in the 12 hours following administration of the test. Early knowledge that a patient is likely to develop AKI may prompt closer patient monitoring and help prevent permanent kidney damage or death, according to the agency.

Read More »
X